Compounds > emivirine
Page last updated: 2024-12-06

emivirine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Emivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was developed for the treatment of HIV infection. It was synthesized by researchers at DuPont Merck Pharmaceutical Company in the 1990s. Emivirine works by binding to the reverse transcriptase enzyme of HIV, preventing it from converting the virus's RNA into DNA. This process is crucial for the virus's replication, and by inhibiting it, emivirine effectively stops the virus from multiplying. Emivirine was initially investigated for its potential as a single-dose treatment for HIV, but it was later found to be more effective when used in combination with other antiretroviral drugs. However, emivirine was ultimately discontinued from development due to concerns about potential side effects, including liver toxicity. Despite its clinical discontinuation, emivirine's synthesis and its effects on HIV reverse transcriptase remain valuable insights for the development of new antiretroviral therapies. It serves as a crucial example of the ongoing research and development efforts in the fight against HIV, highlighting the importance of studying and understanding the mechanisms of viral replication and the interactions of drugs with viral enzymes.'

emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65013
CHEMBL ID35033
CHEBI ID44143
SCHEMBL ID140546
MeSH IDM0222995

Synonyms (45)

Synonym
1etome6bz5i-pr-u
drg-0302
emivirine [usan:inn]
1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-2,4(1h,3h)-pyrimidinedione
bdbm2337
chembl35033 ,
coactinon
6-benzyl-1-(ethoxymethyl)-5-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
6-benzyl-1-(ethoxymethyl)-5-isopropyl-pyrimidine-2,4-dione
coactinon (tm)
149950-60-7
2,4(1h,3h)-pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-
mkc-442
emivirine
i-ebu
6-benzyl-1-(ethoxymethyl)-5-isopropyluracil
hept deriv.
6-benzyl-1-ethoxymethyl-5-isopropyl uracil
1RT1
coactinon (tn)
emivirine (usan/inn)
D01055
chebi:44143 ,
1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1h,3h)-dione
6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil
DB08188
6-benzyl-1-(ethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
6-benzyl-1-(ethoxymethyl)-5-(propan-2-yl)pyrimidine-2,4(1h,3h)-dione
x87g8ix72o ,
unii-x87g8ix72o
6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1h,3h)-dione ,
AKOS015913753
6-benzyl-1-ethoxymethyl-5-isopropyluracil
MLILORUFDVLTSP-UHFFFAOYSA-N
SCHEMBL140546
emivirine [mart.]
emivirine [usan]
emivirine [who-dd]
emivirine [inn]
DTXSID80164437
6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1h,3h)-dione
Q906062
SB58684
HY-15353
CS-0005980

Research Excerpts

Overview

Emivirine (EMV) is a non-nucleoside reverse transcriptase inhibitor currently undergoing Phase III clinical trials in HIV-1-infected patients.

ExcerptReferenceRelevance
"Emivirine (EMV) is a non-nucleoside reverse transcriptase inhibitor currently undergoing Phase III clinical trials in HIV-1-infected patients. "( Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Baba, M; Nitanda, T; Somekawa, K; Wang, X; Yuasa, S, 2001)		2.05

Toxicity

ExcerptReferenceRelevance
" EMV tested negative for genotoxic activity, and except for decreased feed consumption at the high dose (160 mg/kg/day), with resultant decreases in maternal and fetal body weights, EMV produced no adverse effects in a complete range of reproductive toxicology experiments performed on rats and rabbits."( Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.
Barry, DW; Blum, MR; Borroto-Esoda, K; Endoh, R; Furman, P; Grizzle, TB; Moxham, C; Niwa, T; Painter, GR; Sommadossi, J; Szczech, GM; Yamamoto, M, 2000)		0.54

Compound-Compound Interactions

ExcerptReferenceRelevance
" MKC-442 was evaluated in combination with the nucleoside analogues AZT, ddI and ddC, the non-nucleoside RT inhibitor nevirapine, the HIV-1 proteinase inhibitor Ro-31-8959, and the alpha-glucosidase 1 inhibitor, MDL-28,574, using a cell viability assay."( The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS, 1995)		0.29
"When MKC-442 was combined with 3TC and ZDV, they synergistically suppressed HIV-1 replication in MT-4 cells over a wide range of doses irrespective of the endpoints for synergy calculations."( Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Baba, M; Nakade, K; Piras, G; Yuasa, S, 1997)		0.3
"Our results demonstrate a potential efficacy of MKC-442 in combination with 3TC and ZDV, and the three-drug combination should be considered for treatment of AIDS patients."( Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Baba, M; Nakade, K; Piras, G; Yuasa, S, 1997)		0.3
" In this study, the anti-HIV-1 activity of EMV in combination with two nucleoside reverse transcriptase inhibitors was examined in cell cultures."( Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Baba, M; Nitanda, T; Somekawa, K; Wang, X; Yuasa, S, 2001)		0.61

Dosage Studied

ExcerptRelevanceReference
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."( What they say about: non-nucleoside drugs.
, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
HIV-1 reverse transcriptase inhibitorAn entity which inhibits the activity of HIV-1 reverse transcriptase.
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hiv-1 Reverse TranscriptaseHuman immunodeficiency virus 1IC50 (µMol)0.00800.00600.00700.0080AID977608
Chain A, HIV-1 REVERSE TRANSCRIPTASEHuman immunodeficiency virus 1IC50 (µMol)0.00800.00600.00700.0080AID977608
Chain B, HIV-1 REVERSE TRANSCRIPTASEHuman immunodeficiency virus 1IC50 (µMol)0.00800.00600.00700.0080AID977608
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.04000.00060.91418.3200AID1795384; AID1795386; AID1795396
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.31420.00011.076810.0000AID197925; AID198094; AID198228; AID198229; AID198231; AID198238; AID199103; AID481177; AID666410
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.00750.00040.61539.7000AID199991; AID199996; AID200003; AID200009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.00400.00091.30738.0000AID199980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (122)

Assay IDTitleYearJournalArticle
AID246466Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID246467Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID666410Inhibition of HIV1 reverse transcriptase using poly(ra)/oligo(dT)15 homopolymer template as substrate after 1 hr2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID155273Ability to inhibit the replication of RT-MDR (V106A) strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID246557Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID155280Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain RT-MDR(V106A) in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID1157586Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID197925Concentration required to inhibit the HIV-1 reverse transcriptase activity by 50%.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID142319Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 0.05 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID247501Inhibitory activity against HIV-1 mutant strain 181C2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID235859CC50/EC50 ratio of the compound2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID155289Compound was evaluated for inhibition of p24 production in HIV infected peripheral blood mononuclear cells1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.
AID247617Inhibitory activity against HIV-1 double mutants strain 100I and 103N2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID81424Anti-HIV-1 activity determined as dose required to reduce p24 antigen levels.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID246506Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID247620Inhibitory activity against HIV-1 double mutants strain 227L and 106A2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID313191Antiviral activity against HIV1 HTLV-3B2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID155275Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 (Y181C) in peripheral blood mononuclear cells (PBMC); Not determined1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID228281Compound was evaluated for the cytotoxic activity by using Microculture Tetrazolium assay (MTA)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID246390Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in CEM wild type cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID252950Selectivity index of cytotoxic activity (CC50) to inhibitory activity (IC50) relative to LAI cell line2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID105701Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID155288Compound was evaluated for cytotoxic activity against peripheral blood mononuclear cells using microculture tetrazolium assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.
AID142320Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 0.5 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID235870Ratio of CC50 to that EC50 in mock infected cells2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID102402Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
AID1157585Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID142326Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 50 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID106978Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID81420Anti-HIV-1 activity determined as dose required to reduce p24 antigen levels.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID200176Compound was evaluated for enzymatic inhibitory activity against recombinant HIV reverse transcriptase; ND means Not Determined1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.
AID247495Inhibitory activity against HIV-1 mutant strain 100I2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID313194Antiviral activity against HIV1 K103N/Y181C mutant2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID247504Inhibitory activity against HIV-1 mutant strain 190S2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID247503Inhibitory activity against HIV-1 mutant strain 190A2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID104939The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID246579Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID105320Effective dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathogenicity2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID198094Inhibitory activity against HIV-1 recombinant reverse transcriptase.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID157405The effective concentration required to achieve 50% protection of human peripheral blood lymphocytes against the cytopathic effect of HIV-1 virus HTLV-IIIB strain1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID226235Fold resistance (L100I/ WT) was determined2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID199991Effective concentration required against L100I mutant HIV-1 reverse transcriptase2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1157582Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID199103Inhibitory concentration required to inhibit the HIV-1 reverse transcriptase activity2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID152660Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17; Not determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID105513Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID198231Inhibition of purified recombinant HIV-1 reverse transcriptase1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID247496Inhibitory activity against HIV-1 mutant strain 101E2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID247618Inhibitory activity against HIV-1 double mutants strain 101E and 103N2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID247499Inhibitory activity against HIV-1 mutant strain 138K2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID235475Selectivity index is the ratio between CD50 and IC50 values of the compound1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones.
AID155272Ability to inhibit the replication of HTLV IIIb strain of HIV-1 p24 antigen production in PBMC1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID104938Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID247619Inhibitory activity against HIV-1 double mutants strain 103N and 181C2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID199996Effective concentration required against wild type HIV-1 reverse transcriptase2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID102400Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C)1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
AID155134Ability to inhibit the replication of A17 (Y181C) strain of HIV-1 p24 antigen production in PBMC; Not determined1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID247500Inhibitory activity against HIV-1 mutant strain 179E2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID106745Cytotoxicity against MT-4 cells.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1157587Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID81425Anti-HIV-1 activity determined as dose required to reduce p24 antigen levels.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID142321Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 50 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID198228Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID235474Selectivity index is the ratio between CD50 and ED501996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID235708Selectivity index measured as the ratio of CC50 / EC50.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID245969Cytotoxic concentration was measured in CEM wild-type/thymidine-kinase-deficient CEM Cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID105704Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID313190Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID1157580Cytotoxicity against human MT4 cells after 96 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID246558Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID481177Inhibition of HIV1 reverse transcriptase by ELISA2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID235633Selectivity index is the ratio of 50% cytotoxic concentration to IC50 against LAI strain in MT-4 cells by the MTT method was determined2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1157584Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID104761Cytotoxicity against mock-infected MT-4 cells.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID245944Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID200003Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
AID198238Inhibitory activity against HIV-1 reverse transcriptase1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
AID105515The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID313192Antiviral activity against efavirenz-resistant HIV12008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID155277Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 variant (Y181C,K103N) in peripheral blood mononuclear cells (PBMC); Not determined1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID102399Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
AID102398Compound was tested for its cytotoxicity depending on the viability of mock-infected cells1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
AID313189Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID104945Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID155271Ability to inhibit the replication of A17 variant (Y181C,K103N) strain of HIV-1 p24 antigen production in PBMC; Not determined1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID104787Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID142327Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 5 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID157399The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID152661Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain HTLV IIIB wild type.1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID104940The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID152658Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17 variant; Not determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID105695Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID313193Antiviral activity against HIV1 Y181C mutant2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
AID106767Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells by 50%1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID157558Cytotoxic concentration was evaluated using microculture tetrazolium assay (MTA)1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID105530Effective dose of compound required to inhibit 50% of HIV-1 antigen production in MT-4 cultures.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID247526Inhibitory activity against wild type HIV-1 LAI cell line2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID198229Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system1999Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID105514The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID104311Effective dose required for 50% inhibition of HIV-1 antigen production in MT-4 cultures1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones.
AID102401Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-31999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
AID142322Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 5 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID200009Inhibitory concentration against HIV-1 reverse transcriptase1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
AID1157583Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID142325Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 0.5 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID155278Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain HTLV IIIB in peripheral blood mononuclear cells (PBMC)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID246644Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in thymidine-kinase-deficient CEM cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID142324Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 0.05 uM1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID1157581Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID247498Inhibitory activity against HIV-1 mutant strain 106A2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID105143Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID246391Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in MT-4 infected cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.
AID247505Inhibitory activity against HIV-1 mutant strain 227C2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID152775Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain RT-MDR.1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID247502Inhibitory activity against HIV-1 mutant strain 188L2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID247497Inhibitory activity against HIV-1 mutant strain 103N2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1795384HIV-1 RT Assay from Article 10.1021/jm010853h: \\Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibit2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1795396HIV-1 RT Assay from Article 10.1021/jm0309856: \\Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID1795386HIV-1 RT Assay from Article 10.1021/jm980260f: \\5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.\\1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (37.74)18.2507
2000's26 (49.06)29.6817
2010's7 (13.21)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.89 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.82%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive [NCT00002412]Phase 20 participants InterventionalCompleted
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) f [NCT00002418]Phase 225 participants InterventionalTerminated
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Rescriptor (Delavirdine Mesylate), and MKC-442 (With or Without Hy [NCT00002420]Phase 225 participants InterventionalTerminated
An Open Label Study of MKC-442 in at Least Triple Drug Combination in Patients Previously Treated With Nucleoside Reverse Transcriptase and Protease Inhibitors and Who Are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors [NCT00002413]Phase 20 participants InterventionalCompleted
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive [NCT00002215]0 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		8.12436-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine
[no description available]		1.9910pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		10.12393pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
nsc 615985
NSC 615985: structure given in first source; potent inhibitor of HIV reproduction		2.0210
ag-1549
capravirine: a non-nucleoside reverse transcriptase inhibitor		2.0210
aurintricarboxylic acid
Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.		2.0210monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil: an anti-HIV agent; structure in first source. 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by ethoxymethyl, isopropyl, and 3,5-dimethylbenzyl groups, respectively.		3.150pyrimidone
loviride
loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase		2.4120
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		5.51210cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil : A pyrimidone that is uracil in which positions 1, 5, and 6 are substituted by ethoxymethyl, isopropyl, and phenylsulfanyl groups, respectively.		2.6930aryl sulfide;
pyrimidone
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		4.4970aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.730mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
soman
Soman: An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent.		3.110phosphonic ester
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		2.0610catechinantioxidant;
plant metabolite
thiazoles
[no description available]		1.99101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thymidine monophosphate
Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).		2.0210thymidine 5'-monophosphatefundamental metabolite
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		2.0210
pinacolyl methylphosphonic acid
pinacolyl methylphosphonic acid: structure in first source		3.110
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.4220dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		1.9810pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.0510diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		4.08150azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
celgosivir
celgosivir: inhibits glycoprotein processing & the growth of HIVs		1.9810
lamivudine
[no description available]		2.9140monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		3.1106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
trifluoromethanesulfonic acid
trifluoromethanesulfonic acid: deblocking reagent for peptide synthesis; RN given refers to parent cpd. triflic acid : A one-carbon compound that is methanesulfonic acid in which the hydrogens attached to the methyl carbon have been replaced by fluorines.		1.9910one-carbon compound;
perfluoroalkanesulfonic acid
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		5.06130acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		3.3970aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil: inhibits human HIV-1; structure given in first source		2.6930
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.0610flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
gallocatechol
gallocatechol: structure give in first source; RN given for (trans-(+-))-omer; inhibits DNA-dependent DNA & RNA polymerases. (+)-gallocatechin : A gallocatechin that has (2R,3S)-configuration. It is found in green tea and bananas.. gallocatechin : A catechin that is a flavan substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7 (the trans isomer). It is isolated from Acacia mearnsii.		2.0610gallocatechinantioxidant;
metabolite;
radical scavenger
zidovudine triphosphate
[no description available]		1.9810
5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil
[no description available]		2.6930
diethylaminosulfur trifluoride
diethylaminosulfur trifluoride: fluorinating agent for carbohydrates		2.0510
gw420867x
GW420867X: structure in first source		2.730
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		3.110divalent inorganic anion;
phosphite ion
etravirine
[no description available]		2.4820aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
dapivirine
Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission		2.110
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		2.4220L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		3.5202,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
tnk-651
TNK-651: Reverse Transcriptase Inhibitor; structure in first source. 6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by benzyloxymethyl, isopropyl, and benzyl groups, respectively.		8.1350pyrimidone
e-ebu-dm
[no description available]		2.6830
12-hydroxynevirapine
12-hydroxynevirapine : A dipyridodiazepine that is nevirapine in which one of the hydrogens of the methyl group has been substituted by a hydroxy group. It is a metabolite of the anti-HIV drug, nevirapine.		2.4120aromatic primary alcohol;
cyclopropanes;
dipyridodiazepine		drug metabolite
dpc 961
[no description available]		2.0210
3-dimethylamino-4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1h)-one
3-dimethylamino-4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1H)-one: structure in first source		2.4220
r 82150
R 82150: structure given in first source; inhibits HIV-1 replication		2.0110
r-82913
R-82913: antiviral target on reverse transcriptase of HIV-1		2.4120
r 86183
[no description available]		2.4220
nsc 629243
NSC 629243: structure given in first source; an anti-HIV drug		2.4220
hby 097
HBY 097: a quinoxaline derivative		2.0110
hi 236
[no description available]		210
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		3.150
uc-781
[no description available]		2.9240
ly 73497
LY 73497: HIV-1 reverse transcriptase inhibitor; structure in first source		2.4220
dolutegravir
[no description available]		6.9133difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.420purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
oxypurinol
Oxypurinol: A xanthine oxidase inhibitor.. alloxanthine : A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6.		7.0310pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		3.1250
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		011.08159
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		113.08159
Complications, Infectious Pregnancy
[description not available]		09.8299
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		09.86109
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.6930